Close Menu

mergers & acquisitions

MyHeritage plans to offer Promethease free of charge through the end of this year and to maintain SNPedia as a free resource for academic and non-profit users.

The Genome Sensor — the first product Cardea will market under the Nanosens brand — will allow the user to Google a genome using a single guide RNA.

The companies also launched an early-access program for their first CRISPR-Chip-based product, the Genome Sensor.

OncoCyte believes Razor's CLIA-validated lung cancer prognostic test will complement its in-development DetermaVu lung cancer detection assay.

The combined firm will be based in Gaithersburg, Maryland and will focus on infectious disease diagnostics and antimicrobial resistance prediction services. 

The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.

The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

Pages

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.